新出现市场报道时间 2026-10-07 18:16

Perspective Therapeutics 公司宣布 [212Pb]VMT-α-NET 数据已被接受，将在 NANETS 会议上进行展示。

Perspective Therapeutics，一家放射性药物公司，其[212Pb]VMT-α-NET项目的数据已被接受在NANETS 2026多学科NET医学研讨会进行展示，突显了其在神经内分泌肿瘤治疗方面的持续研究。

为什么重要. 投资者和医疗专业人士将深入了解[212Pb]VMT-α-NET治疗神经内分泌肿瘤的疗效和安全性。

影响到谁

1Perspective Therapeutics, Inc.
制造 →事实
2Clinical drug product candidates产品
使用 →事实
3Lead-212材料
使用 →事实
4Lead-212 (²¹²Pb)材料
使用 →事实
5Radium-224/Lead-212 generator platform技术

证据

GGlobeNewswire public company news公司披露2026-10-07 18:16
The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
查看来源
GGlobeNewswire public company news公司披露2026-10-07 18:16
The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).
查看来源
GGlobeNewswire public company news公司披露2026-10-07 18:16
The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candi…
查看来源
GGlobeNewswire public company news公司披露2026-10-07 18:16
SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that d…
查看来源
GGlobeNewswire public company news公司披露2026-10-07 18:16
Perspective designed [212Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion s…
查看来源